{"id":3004,"date":"2017-09-21T15:31:59","date_gmt":"2017-09-21T19:31:59","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3004"},"modified":"2017-09-21T15:31:59","modified_gmt":"2017-09-21T19:31:59","slug":"deciphera-pharmaceuticals-dcph-ipo-preview","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/deciphera-pharmaceuticals-dcph-ipo-preview\/","title":{"rendered":"Deciphera Pharmaceuticals (DCPH) IPO Preview"},"content":{"rendered":"<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.14.08-PM.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter size-full wp-image-3005\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.14.08-PM.png\" alt=\"Screen Shot 2017-09-21 at 3.14.08 PM\" width=\"369\" height=\"139\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.14.08-PM.png 369w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.14.08-PM-300x113.png 300w\" sizes=\"(max-width: 369px) 100vw, 369px\" \/><\/a><\/p>\n<p>Company: <strong>Deciphera Pharmaceuticals<\/strong><br \/>\nSymbol: DCPH<br \/>\nDescription: They are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies.<br \/>\nShares: 6.25 million<br \/>\nPrice Range: $15.00-$17.00<br \/>\nTrade Date: 9\/28<br \/>\nUnderwriter(s): J.P. Morgan, Piper Jaffray<br \/>\nCo-Manager(s): JMP Securities, Nomura<\/p>\n<p><a href=\"https:\/\/www.motifinvesting.com\/ipos\/deciphera?utm_medium=partner&amp;utm_source=ipo-boutique&amp;utm_campaign=ipo\" target=\"_blank\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-3009\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.10.27-PM.png\" alt=\"DeciPheraMotifLogo\" width=\"820\" height=\"62\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.10.27-PM.png 820w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.10.27-PM-600x45.png 600w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.10.27-PM-300x23.png 300w\" sizes=\"(max-width: 820px) 100vw, 820px\" \/><\/a><\/p>\n<p><strong><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1654151\/000119312517286735\/d364141ds1a.htm\" target=\"_blank\">Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.retailroadshow.com\/wp\/roadshows.asp\" target=\"_blank\">Link to Retail Roadshow<\/a><\/strong><\/p>\n<p><strong>Business<\/strong>:\u00a0Their targeted, small molecule drug candidates, designed using their\u00a0proprietary kinase switch control inhibitor platform, inhibit the activation of kinases, an important family of enzymes, that, when mutated or over expressed, are known to be directly involved in the growth and spread of many cancers. They\u00a0have built a diverse pipeline of wholly owned, orally administered drug candidates that include three clinical-stage and two research-stage programs. They\u00a0have designed our lead drug candidate DCC-2618 to inhibit the full spectrum of mutant or amplified KIT and PDGFR\u03b1 kinases that drive cancers such as gastrointestinal stromal tumors, or GIST.<\/p>\n<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.16.00-PM.png\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-3006\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.16.00-PM.png\" alt=\"DecipheraPharmaDrugs\" width=\"552\" height=\"306\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.16.00-PM.png 552w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.16.00-PM-300x166.png 300w\" sizes=\"(max-width: 552px) 100vw, 552px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Competition and Sector Performance: \u00a0Healthcare Related IPOs as of 9.21.17pm<\/strong><\/p>\n<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.26.52-PM.png\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-3008\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.26.52-PM.png\" alt=\"HealthCareIPOs09212017\" width=\"1031\" height=\"695\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.26.52-PM.png 1031w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.26.52-PM-600x404.png 600w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.26.52-PM-300x202.png 300w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/09\/Screen-Shot-2017-09-21-at-3.26.52-PM-1024x690.png 1024w\" sizes=\"(max-width: 1031px) 100vw, 1031px\" \/><\/a><\/p>\n<p><strong>Insider Buying:\u00a0<\/strong>Certain of their\u00a0existing stockholders have indicated an interest in purchasing up to an aggregate of approximately $30\u00a0million of shares of their\u00a0common stock.<\/p>\n<p><strong>Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n<p><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\">IPO Boutique subscription clients receive daily updates on this critical information.<\/a><\/p>\n<p><strong>Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0<a href=\"https:\/\/www.ipoboutique.com\/cgi\/ipo-track-record-summary-report.php\">track record<\/a>\u00a0with our performance for last 12 years at our website.<\/p>\n<p>Indicate with confidence,\u00a0<a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\">SUBSCRIBE<\/a>\u00a0today.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company: Deciphera Pharmaceuticals Symbol: DCPH Description: They are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies. Shares: 6.25 million Price Range: $15.00-$17.00 Trade Date: 9\/28 Underwriter(s): J.P. Morgan, Piper Jaffray[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1346],"class_list":["post-3004","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-dcph"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3004"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3004\/revisions"}],"predecessor-version":[{"id":3010,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3004\/revisions\/3010"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}